Neuroscience News

The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease, but which also carry safety risks according to Knight Initiative for Brain Resilience affiliate Mike Greicius and others.

Why do our brains get worse at learning as we get older, and what can we do about it? Institute affiliate Carla Shatz discusses our brain's capacity for change on this podcast episode.

Most Parkinson’s disease patients struggle with speech problems. New research by Stanford Medicine scientists uncovers the brain connections that could be essential to preserving speech.

This week on From Our Neurons to Yours, we talk with memory expert Anthony Wagner about the nature of memory and how to improve it.

Wu Tsai Neuro and Knight Initiative for Brain Resilience affiliate, Michael Greicius, and others share their expertise on the limitations of the Alzheimer's drug Leqembi.

Seven Stanford faculty, including Knight Initiative Director Tony Wyss-Coray, are among the 502 new fellows of the American Association for the Advancement of Science.

Q&A with Wu Tsai Neuro affiliate Kathleen Poston about her work past and present on Parkinson’s disease. Poston studies the pathophysiology underlying the cognitive, behavioral and motor symptoms characteristic of Parkinson’s.

A dedicated philanthropist and Stanford GSB alum, Knight has provided game-changing support for schools and initiatives across campus.

Pro-inflammatory protein TREM1 in peripheral immune cells may promote age-related cognitive decline and dementia, according to Knight Initiative–funded research.

Recent research supported by the Knight Initiative has identified a link between lipid droplets in the microglia to a known genetic risk factor for AD.

Two new studies supported by the Knight Initiative highlight groundbreaking new early biomarkers for the diagnosis and treatment of neurodegenerative disease.

Research supported by the Knight Initiative found that metformin, a commonly prescribed diabetes drug associated with moderate weight loss, stimulates the production of lac-phe, a molecule abundant after exercise.

A few closely related drugs, all squarely aimed at treating Alzheimer’s disease, have served up what can be charitably described as a lackadaisical performance. Wu Tsai Neuro and Knight Initiative affiliate Mike Greicius explains why.

This week, we sit down with neuroscientist Tony Wyss-Coray to learn about how some of your organs may be aging faster than the rest of you.

This week on From Our Neurons to Yours, we sit down with Stanford neurologist Kathleen Poston to learn about a sea change in our understanding of Parkinson's Disease.

Wu Tsai Neuro affiliate Sharon Sha shared her expertise on Frontotemporal Dementia amid Wendy Williams' diagnosis.